Physician profile
Nathan Lent
NPI 1174934046
$2,164.31
in general payments reported to CMS, 2019-2025
21 companies · $489 in 2025
The $489 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $394 · 2020: $177 · 2021: $67.70 · 2022: $88.03 · 2023: $448 · 2024: $501 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,429 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,428.79 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $708.57 | 2019-2025 | Wegovy |
| Abbott Laboratories | $192.31 | 2022-2025 | Freestyle Libre 3 |
| Abbvie INC. | $186.25 | 2021-2025 | |
| Lilly USA, LLC | $173.65 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $128.25 | 2019-2024 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $111.08 | 2019 | |
| Astellas Pharma US INC | $90.68 | 2019-2025 | Veozah |
| Stryker Corporation | $69.27 | 2023 | Xpress Ent Dilation System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.45 | 2024 | Jardiance, Synjardy, Tradjenta |
| Dexcom, INC. | $61.56 | 2021-2024 | Dexcom G6 Transmitter |
| Gilead Sciences, INC. | $57.34 | 2023 | |
| Global Blood Therapeutics, INC. | $54.55 | 2020 | |
| Inspire Medical Systems, INC. | $43.97 | 2023-2024 | Inspire |
| Intra-Sana Laboratories | $39.39 | 2025 | Glycate, Reltone 400 Mg, Reltone 200 Mg |
| Exact Sciences Corporation | $39.21 | 2023-2024 | Cologuard Collection Kit |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $35.72 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $33.60 | 2020 | |
| Amgen INC. | $29.21 | 2022-2024 | Repatha, Otezla |
| Esperion Therapeutics, INC. | $16.29 | 2021 | |
| Akcea Therapeutics, INC. | $16.28 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $14.68 | 2024 | Crysvita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Lent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.